Clinical Trial

Daridorexant for Alzheimer Disease Prevention

Study acronym: PAD-DORA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-15
Trial Details
NCT Number NCT07213349
Lead Sponsor Douglas Mental Health University Institute
Collaborators: Weston Family Foundation
Conditions Alzheimer Disease (AD)
Enrollment 240 participants
Start Date 2025-10-14
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-19